<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307671</url>
  </required_header>
  <id_info>
    <org_study_id>P040425</org_study_id>
    <nct_id>NCT00307671</nct_id>
  </id_info>
  <brief_title>Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years</brief_title>
  <acronym>CORTAGE</acronym>
  <official_title>Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to lower the morbidity rate in elderly patients affected with
      systemic necrotizing vasculitides, by reducing mortality and improving global outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic necrotizing vasculitides are severe diseases associated with a high mortality rate
      in elderly.

      Although corticosteroids and immunosuppressants are effective, they can induce some
      side-effects, especially in this latter patients.

      Preliminary data indicate that systemic necrotizing vasculitides (SNV) occurring in patients
      over 65 years have a poorer outcome than in younger patients (mortality rate of 76 % vs. 69 %
      at 5 years, respectively) and that 68,4 % of the elderly experience treatment side-effects.

      In this trial, patients will be randomly assigned to receive either low doses of
      corticosteroids systematically in combination with immunosuppressants (CYC then azathioprine)
      or usual regimen with corticosteroids combined with immunosuppressants only if factor(s) of
      poor prognosis is present (this latter regimen relying on previously published therapeutic
      guidelines).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of side effects (morbidity)</measure>
    <time_frame>at 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment (remission rate)</measure>
    <time_frame>during the 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose exposure to OCS and AZA</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative BVAS (AUC), VDI, HAQ-DI, SF-36 values</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Vasculitis</condition>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Churg-Strauss Syndrome</condition>
  <condition>Polyarteritis Nodosa</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>conventional treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>reduction dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone, methylprednisolone,cyclophosphamides</intervention_name>
    <description>treatment conventional</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Azathioprine,prednisone,methylprednisolone</intervention_name>
    <description>reduction dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil,methotrexate</intervention_name>
    <description>in the treatment conventional and in the reduction dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed WG, MPA, PAN without HBV infection, or CSS

          -  Patients can be still be enrolled within 1 month after starting corticosteroids if
             prescribed according to protocol.

          -  within or after the 65th of anniversary

          -  Age ≥ 65 years

        Exclusion Criteria:

          -  Any cytotoxic drug within previous year

          -  Co-existence of another systemic autoimmune disease, e.g., SLE, RA

          -  Virus-associated vasculitides

          -  HIV positivity

          -  Malignancy (usually excluded unless approved by the trial coordinator)

          -  Age &lt; 65 years

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc Guillevin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic necrotizing vasculitides</keyword>
  <keyword>corticosteroids; azathioprine; mycophenolate mofetil;</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Polyarteritis Nodosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

